Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

Mutations in the MET exon 14 RNA splice acceptor and donor sites, which lead to exon skipping, deletion of the juxtamembrane domain containing the Cbl E3-ubiquitin ligase binding site, and decreased turnover of the resultant aberrant MET protein, were previously reported to be oncogenic in preclinic...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Discov
Glavni autori: Paik, Paul K., Drilon, Alexander, Fan, Pang-Dian, Yu, Helena, Rekhtman, Natasha, Ginsberg, Michelle S., Borsu, Laetitia, Schultz, Nikolaus, Berger, Michael F., Rudin, Charles M., Ladanyi, Marc
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4658654/
https://ncbi.nlm.nih.gov/pubmed/25971939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-1467
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items